hERG
7 articles
Computational & AIJournal of Chemical Theory and Computation
Pairing induced fit docking with free energy calculations and a shared binding mode makes flexible, promiscuous anti-target proteins tractable for structure-based design
- Anti-targets such as CYP3A4, CYP2D6, hERG and PXR have large, flexible pockets that bind many ligands, which has made structure-based design against them difficult.
- The workflow combines induced fit docking with free energy perturbation, and requires a consensus binding mode across a congeneric series so that receptor conformations are sampled efficiently.
- It was evaluated retrospectively on public datasets and applied prospectively in ongoing discovery programs, supporting its use for steering compounds away from these liabilities.
The consensus-binding-mode requirement is both the trick and the weak spot. Promiscuous pockets like CYP3A4 and hERG routinely let close analogs flip poses, so FEP will look reliable exactly where the assumption holds and quietly fail where it doesn't. Before trusting it on my series, I'd check whether the method flags pose switches, and whether it beats a simple matched-pair trend on the assay we already run.
Computational & AIJournal of Chemical Theory and Computation (ACS)
Induced-fit docking plus free energy perturbation brings structure-based design to promiscuous ADMET anti-targets
- Combines induced-fit docking with free energy perturbation to model flexible, promiscuous anti-target proteins: CYP3A4, CYP2D6, hERG and PXR.
- Imposing one shared binding pose across a congeneric series lets the workflow sample many receptor conformations efficiently.
- Evaluated retrospectively on public datasets and applied prospectively in ongoing drug discovery programs, supporting lead optimization away from off-target liabilities.
The consensus-pose assumption is both the trick and the risk: for hERG and CYP3A4, ligands in one series can flip modes, and a forced shared pose will quietly bias the ranking. I'd want to see a no-FEP baseline (ligand-based QSAR or simple docking) on the same sets, plus the cases where the pose failed. Prospective use is encouraging, but hit rate is unreported here.
Medicinal ChemistryJournal of Medicinal Chemistry
Re-engineered MCC950 analog gives longer-lasting, orally exposed NLRP3 inhibition with cleaner tolerability
- Tuning the lipophilic and solvent-facing portions of the sulfonylurea MCC950 gave F34, which keeps nanomolar cellular potency and spares the NLRC4 and AIM2 inflammasomes.
- Docking and molecular dynamics place F34 in the MCC950 site; SPR shows direct, micromolar binding to NLRP3.
- In mice F34 has a long half-life and very high oral bioavailability, and outperforms MCC950 in gout and chronic colitis models, with better tolerability and low hERG and CYP liabilities.
Compared with MCC950 and the newer sulfonylurea-free NLRP3 chemotypes, F34 is a conservative edit: the acidic sulfonylurea core, and its liver-safety question, is still there. Docking plus SPR is thin for a binding-mode claim, so I'd want a cryo-EM or co-crystal structure with NLRP3, and chronic-dosing liver data, before believing the improved tolerability.
PharmacologyBritish Journal of Pharmacology (Wiley)
Methadone plus a synthetic cannabinoid worsens cardiac repolarisation, hinting at a hidden overdose risk
- Mortality records of deaths involving synthetic cannabinoids flagged methadone as the co-detected medication most associated with QT risk, and fatal methadone levels looked lower in these mixed cases.
- In isolated guinea pig hearts, methadone alone lengthened the QTc interval, the cannabinoid 5F-ADB alone did not, yet together the effect grew.
- Modelling and patch-clamp work showed 5F-ADB blocks hERG only weakly, so the interaction likely involves more than direct channel inhibition.
This probably is not a channel-block story: 5F-ADB barely touches hERG yet still amplifies methadone's QTc effect. A pharmacokinetic check comes first, namely whether the cannabinoid inhibits CYP-mediated methadone clearance and raises free exposure. Post-mortem levels are also prone to redistribution, so the lower fatal concentrations need a matched methadone-only control before anyone leans on them.
Medicinal ChemistryACS Medicinal Chemistry Letters
Pyridazino-indoles replace the phenol in pyridazine NLRP3 inhibitors
- Indole-fused pyridazines were developed to replace the phenol group of earlier phenol-pyridazine NLRP3 inhibitors.
- Cryo-EM and modeling suggest the indole keeps the key contact with Ala228 in the binding site.
- Two lead compounds reached low-nanomolar potency with good solubility and permeability, and were profiled in mouse pharmacokinetic studies.
- hERG inhibition ended development, though the compounds remain useful in vivo tools; a reactive metabolite audit is also reported.
Replacing the phenol with an indole-fused pyridazine removes phenol liabilities while keeping the Ala228 contact, and potency and solubility look healthy. The cautionary note is hERG ending a series this strong: did the flat, lipophilic fused ring cause it? I would treat these compounds as in vivo tools, not a template to copy without scrutiny.
Computational & AIJournal of Chemical Theory and Computation
Using induced-fit docking plus FEP to design away from CYP, hERG and PXR
- Anti-targets such as CYP3A4, CYP2D6, hERG and PXR have large, flexible sites that make structure-based design difficult.
- The workflow pairs induced-fit docking with free energy perturbation, enforcing a consensus binding mode across a congeneric series to sample receptor conformations efficiently.
- It was tested on public retrospective datasets and applied prospectively in active drug discovery programs.
Most teams treat hERG and CYP as a post-hoc assay problem; getting usable FEP on these promiscuous pockets would move liability into the design cycle. The consensus-binding-mode restriction is the clever bit, but it also limits you to congeneric series. Prospective hit rates on novel scaffolds will show whether this holds beyond the series it was tuned on.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Dialing hERG out of a DCN1–UBE2M inhibitor without losing potency
- The earlier tool compound NAcM-OPT blocked the DCN1–UBE2M interaction, was orally available and slowed xenograft growth, but carried significant hERG affinity that stalled development.
- The authors systematically modified the scaffold to cut hERG binding while keeping DCN1 engagement.
- Lead compound 110 matched the parent in biochemical and cellular potency, with better physicochemical properties and improved selectivity against hERG.
This is the unglamorous but necessary second act: a validated PPI chemotype that was dead on cardiac safety, rescued by SAR alone. The takeaway for anyone with a basic, lipophilic PPI binder is that hERG can often be engineered out without giving up the pharmacophore, so check your own series before abandoning it.